Last month was a tale of two public offerings in biotech. How will the next one fare?
More than a half-dozen hedge funds are gearing up for the next initial public offering of a fledgling biopharma company.
The deal comes in the wake of two biopharma IPOs in June: One company was up double digits after the offering, with the other down double-digits.
Artiva Biotherapeutics said in an updated regulatory filing it expects to sell 8.7 million shares for between $14 and $16 per share. At the high end of the anticipated price range, the company expects to raise as much as $139 million.
Content retrieved from: https://www.institutionalinvestor.com/article/2dib4t1b50utwp2096z28/hedge-funds/amid-mixed-ipo-signals-hedge-funds-gear-up-for-upcoming-deal.
